Our Pipeline

Pipeline and Life Cycle Management

Overview

Pharma Two B is completing the clinical development of P2B001 for the treatment of early stage PD patients. The company is considering P2B001’s life cycle management in the treatment of advanced PD patients. In addition, P2B001 may potentially have disease modifying effects that can delay motor complications at the early stages of the disease. A study to demonstrate that effect is under discussion.

Additionally, Pharma Two B is building its pipeline portfolio of products, based on its proprietary rasagiline extended release dosage form within its unique combination technology to address other important unmet medical needs in the CNS therapeutic area.

P2B001 for Advanced PD Patients

Pharma Two B is considering P2B001 for the treatment of more advanced Parkinson’s disease patients who are using Levodopa.

Levodopa is the gold standard for advanced Parkinson’s disease. However, it is associated with motor complications such as motor fluctuations and dyskinesia. These usually occur with prolonged use and increased doses due to disease progression and may limit the effectiveness of the levodopa. Using P2B001 as add-on to low dose levodopa, may help keep the levodopa dose as low as possible for as long as possible, without compromising efficacy.

A phase III clinical trial evaluating the advantage of P2B001 as add-on to Levodopa is planned soon. For information regarding planned clinical studies please contact us.

P2B001 – Delays Motor Complications for Early Stage PD Patients

Pharma Two B is considering P2B001 as a disease modifying agent for the treatment of early PD patients who require dopaminergic therapy.

Both components of P2B001 rasagiline and pramipexole have strong preclinical and clinical support for potential disease modification. P2B001’s long-term study to delay motor complications relies on the potential involvement of disease modification mechanisms of both rasagiline and pramipexole.

A long term clinical trial evaluating the advantage of P2B001 as delaying motor complications is planned in the near future. For information regarding planned clinical studies please contact us.